Published :
Tables : 60
Figures : 50
Category : Healthcare
No. of Pages : 223
Report Code : HC-U3360
Platelet Rich Plasma Market is estimated to value over USD 430 million by 2027 end with a CAGR of over 13% during the forecast period 2020 to 2027. The platelet rich plasma is crucial for the healthcare industry, particularly in cosmetic and orthopedic surgical procedures. This procedure can treat injuries like tennis elbow, tendon cuffs, hamstring and rotator cuff, thereby healing the patient effectively. Furthermore, many sport-related injuries are healed with platelet rich plasma therapy. Even medical conditions like facelift surgeries and erectile dysfunction are also being treated using this therapy technique. The therapy includes collecting blood samples and separating the platelets using centrifuges. These platelets are then injected on the injury point for accelerating the process of healing. The procedure is allergy and risk-free as the blood used for the patient is of the patient itself. Rising ageing population and growing prevalence of orthopedic conditions are some other factors propelling the platelet rich plasma market growth. AS pe the National Center for Biotechnology Information, over 1.4 million people are diagnosed with fractures related to osteoporosis every year. Additionally, rising awareness pertaining to platelet rich plasma therapy for dental treatment is predicted to boost the market proliferation. Market Segmentation: By Type Pure Platelet-rich Plasma Leukocyte Platelet-rich Plasma Pure Platelet-rich Fibrin Leukocyte Platelet-rich Fibrin By Origin Autologous Platelet-rich Plasma Allogeneic Platelet-rich Plasma Homologus Platelet-rich Plasma By Application Cosmetic Surgery Skin Care Hair Care Orthopedic Surgery Ophthalmic Surgery Dentistry Cardiac Surgery Neurosurgery Other Indications By End-User Physician's office/Private Practice Hospitals Orthopedic Clinics Ophthalmic Clinics Cosmetic/Dermatology/Trichology Clinics Academic & Research Institutes By Region • North America • Latin America • Europe • Asia-Pacific • Middle East and Africa The global market is classified into product, application and region. The product segment is fragmented into leukocyte rich PRP, pure PRP and leukocyte fibrin PRP. The pure PRP held the largest platelet rich plasma market share and it is predicted to do so during the forecast period. This is mainly due to its capability of eliminating neutrophils, a WBC type consisting of components that are inflammatory in nature, which is likely to cause pain once the treatment is completed. Conversely, the leukocyte-rich fibrin PRP is anticipated to grow substantially during the forecast period. This PRP technique improves the process of healing, thereby reducing the overall recovering time. Furthermore, they consist of organic healing proteins, which creates a cell network that accelerates the process of healing, thereby bettering the regeneration of bones. The application segment is bifurcated into orthopaedics, ophthalmic surgery, cosmetic surgery and neurosurgery. The orthopaedics segment subjugated the market owing to arise in the number of patients diagnosed with orthopaedic conditions like tennis elbow, Achilles tendon injuries, rotator cuff, hamstring can be successfully treated with PRP. The technique helps in reducing injury recurrence which shall reduce the chance of surgical intervention. Regional Analysis: The North America region is predicted to subjugate the market owing to a wide range of applications along with a rise in the number of patients diagnosed with orthopaedic conditions. Furthermore, a strong presence of key market players is another factor bolstering the growth of the market. Competitive Landscape: Some of the key market players are T-Biotechnology (T-LAB), Arthrex, Inc., Terumo BCT, Inc., EmCyte Corporation, DePuy Synthes, Zimmer Biomet, Stryker; Glofinn Oy, DR. PRP AMERICA, LLC. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global platelet rich plasma market by type, by origin, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The platelet rich plasma is crucial for the healthcare industry, particularly in cosmetic and orthopedic surgical procedures. This procedure can treat injuries like tennis elbow, tendon cuffs, hamstring and rotator cuff, thereby healing the patient effectively. Furthermore, many sport-related injuries are healed with platelet rich plasma therapy. Even medical conditions like facelift surgeries and erectile dysfunction are also being treated using this therapy technique. The therapy includes collecting blood samples and separating the platelets using centrifuges. These platelets are then injected on the injury point for accelerating the process of healing. The procedure is allergy and risk-free as the blood used for the patient is of the patient itself. Rising ageing population and growing prevalence of orthopedic conditions are some other factors propelling the platelet rich plasma market growth. AS pe the National Center for Biotechnology Information, over 1.4 million people are diagnosed with fractures related to osteoporosis every year. Additionally, rising awareness pertaining to platelet rich plasma therapy for dental treatment is predicted to boost the market proliferation.
Market Segmentation:
By Type
By Origin
By Application
By End-User
By Region • North America • Latin America • Europe • Asia-Pacific • Middle East and Africa
The global market is classified into product, application and region. The product segment is fragmented into leukocyte rich PRP, pure PRP and leukocyte fibrin PRP. The pure PRP held the largest platelet rich plasma market share and it is predicted to do so during the forecast period. This is mainly due to its capability of eliminating neutrophils, a WBC type consisting of components that are inflammatory in nature, which is likely to cause pain once the treatment is completed. Conversely, the leukocyte-rich fibrin PRP is anticipated to grow substantially during the forecast period. This PRP technique improves the process of healing, thereby reducing the overall recovering time. Furthermore, they consist of organic healing proteins, which creates a cell network that accelerates the process of healing, thereby bettering the regeneration of bones. The application segment is bifurcated into orthopaedics, ophthalmic surgery, cosmetic surgery and neurosurgery. The orthopaedics segment subjugated the market owing to arise in the number of patients diagnosed with orthopaedic conditions like tennis elbow, Achilles tendon injuries, rotator cuff, hamstring can be successfully treated with PRP. The technique helps in reducing injury recurrence which shall reduce the chance of surgical intervention.
Regional Analysis:
The North America region is predicted to subjugate the market owing to a wide range of applications along with a rise in the number of patients diagnosed with orthopaedic conditions. Furthermore, a strong presence of key market players is another factor bolstering the growth of the market.
Competitive Landscape:
Some of the key market players are T-Biotechnology (T-LAB), Arthrex, Inc., Terumo BCT, Inc., EmCyte Corporation, DePuy Synthes, Zimmer Biomet, Stryker; Glofinn Oy, DR. PRP AMERICA, LLC.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global platelet rich plasma market by type, by origin, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Platelet Rich Plasma Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Platelet Rich Plasma Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Platelet Rich Plasma Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Platelet Rich Plasma Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Platelet Rich Plasma Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million & Number of Patients) 7.1. Pure Platelet-rich Plasma 7.2. Leukocyte Platelet-rich Plasma 7.3. Pure Platelet-rich Fibrin 7.4. Leukocyte Platelet-rich Fibrin 8. Global Platelet Rich Plasma Market, By Origin Historical Analysis and Forecast 2020-2027 (USD Million & Number of Patients) 8.1. Autologous Platelet-rich Plasma 8.2. Allogeneic Platelet-rich Plasma 8.3. Homologus Platelet-rich Plasma 9. Global Platelet Rich Plasma Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million & Number of Patients) 9.1. Cosmetic Surgery 9.1.1. Skin Care 9.1.2. Hair Care 9.2. Orthopedic Surgery 9.3. Ophthalmic Surgery 9.4. Dentistry 9.5. Cardiac Surgery 9.6. Neurosurgery 9.7. Other Indications 10. Global Platelet Rich Plasma Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million & Number of Patients) 10.1. Physician's office/Private Practice 10.2. Hospitals 10.3. Orthopedic Clinics 10.4. Ophthalmic Clinics 10.5. Cosmetic/Dermatology/Trichology Clinics 10.6. Academic & Research Institutes 11. North America Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) along with expected regulatory needs 11.1. Introduction 11.2. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million & Number of Patients) Forecast for North America 2020-2027 12. Latin America Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) 12.1. Introduction 12.2. Regional Market Trends 12.3. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 12.3.1. Brazil 12.3.2. Venezuela 12.3.3. Argentina 12.3.4. Rest of Latin America 12.4. Market Size (USD Million & Number of Patients) Forecast for Latin America 2020-2027 13. Europe Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) 13.1. Introduction 13.2. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Switzerland 13.2.9. Netherlands 13.2.10. Rest of Western Europe 13.3. Market Size (USD Million & Number of Patients) Forecast for Europe 2020-2027 14. Asia Pacific Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) 14.1. Introduction 14.2. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. Singapore 14.2.4. India 14.2.5. Australia and New Zealand 14.2.6. ASEAN (Malaysia, Thailand, Indonesia, Philippines and Vietnam) 14.2.7. South Korea 14.2.8. Taiwan 14.2.9. Rest of Asia Pacific 14.3. Market Size (USD Million & Number of Patients) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) 15.1. Introduction 15.2. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million & Number of Patients) Forecast for MEA 2020-2027 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, By Type and Disease Indication Portfolio, Financial Layouts) 17.1. T-Biotechnology (T-LAB) 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Arthrex, Inc. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3 Terumo BCT, Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. EmCyte Corporation 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. DePuy Synthes 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Zimmer Biomet 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Stryker 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Glofinn Oy 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. DR. PRP AMERICA LLC 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Johnson & Johnson 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11. Exactech, Inc 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12. Biotest Aktiengesellschaft 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13. CSL Limited 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Platelet Rich Plasma Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Platelet Rich Plasma Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Platelet Rich Plasma Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Platelet Rich Plasma Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Platelet Rich Plasma Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million & Number of Patients) 7.1. Pure Platelet-rich Plasma 7.2. Leukocyte Platelet-rich Plasma 7.3. Pure Platelet-rich Fibrin 7.4. Leukocyte Platelet-rich Fibrin
8. Global Platelet Rich Plasma Market, By Origin Historical Analysis and Forecast 2020-2027 (USD Million & Number of Patients) 8.1. Autologous Platelet-rich Plasma 8.2. Allogeneic Platelet-rich Plasma 8.3. Homologus Platelet-rich Plasma
9. Global Platelet Rich Plasma Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million & Number of Patients) 9.1. Cosmetic Surgery 9.1.1. Skin Care 9.1.2. Hair Care 9.2. Orthopedic Surgery 9.3. Ophthalmic Surgery 9.4. Dentistry 9.5. Cardiac Surgery 9.6. Neurosurgery 9.7. Other Indications
10. Global Platelet Rich Plasma Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million & Number of Patients) 10.1. Physician's office/Private Practice 10.2. Hospitals 10.3. Orthopedic Clinics 10.4. Ophthalmic Clinics 10.5. Cosmetic/Dermatology/Trichology Clinics 10.6. Academic & Research Institutes
11. North America Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) along with expected regulatory needs 11.1. Introduction 11.2. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million & Number of Patients) Forecast for North America 2020-2027
12. Latin America Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) 12.1. Introduction 12.2. Regional Market Trends 12.3. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 12.3.1. Brazil 12.3.2. Venezuela 12.3.3. Argentina 12.3.4. Rest of Latin America 12.4. Market Size (USD Million & Number of Patients) Forecast for Latin America 2020-2027
13. Europe Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) 13.1. Introduction 13.2. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Switzerland 13.2.9. Netherlands 13.2.10. Rest of Western Europe 13.3. Market Size (USD Million & Number of Patients) Forecast for Europe 2020-2027
14. Asia Pacific Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) 14.1. Introduction 14.2. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. Singapore 14.2.4. India 14.2.5. Australia and New Zealand 14.2.6. ASEAN (Malaysia, Thailand, Indonesia, Philippines and Vietnam) 14.2.7. South Korea 14.2.8. Taiwan 14.2.9. Rest of Asia Pacific 14.3. Market Size (USD Million & Number of Patients) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Platelet Rich Plasma Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million & Number of Patients) 15.1. Introduction 15.2. Historical Market Size (USD Million & Number of Patients) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million & Number of Patients) Forecast for MEA 2020-2027
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, By Type and Disease Indication Portfolio, Financial Layouts) 17.1. T-Biotechnology (T-LAB) 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Arthrex, Inc. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3 Terumo BCT, Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. EmCyte Corporation 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. DePuy Synthes 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Zimmer Biomet 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Stryker 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Glofinn Oy 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. DR. PRP AMERICA LLC 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Johnson & Johnson 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11. Exactech, Inc 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12. Biotest Aktiengesellschaft 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13. CSL Limited 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview
18. Pre and Post COVID-19 Impact
18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics